[144] Ingredion Incorporated SEC Filing

Rhea-AI Filing Summary

Ingredion's Form 144 notifies a proposed sale of 36,287 shares of common stock on the NYSE with an aggregate market value of $4,591,152.89. The filing lists 64,180,890 shares outstanding, and the sale is scheduled approximately for 08/12/2025 through Fidelity Brokerage Services LLC.

The securities were acquired the same day by stock option exercise from the issuer, with payment in cash. The filer reports no securities sold in the past three months and includes the standard representation that no material nonpublic information is known to the selling person.

Insights

Financial Analyst

TL;DR A routine Form 144 shows an exercised option and planned sale of 36,287 Ingredion shares valued at $4.59M; not a market-moving quantity.

The filing documents a single proposed sale of 36,287 common shares with an aggregate market value of $4,591,152.89 to be executed on the NYSE via Fidelity. The shares were acquired on the same date by stock option exercise and paid in cash. The filer notes no sales in the prior three months and makes the standard representation about material nonpublic information. Given the absolute and relative size shown, this appears to be a routine insider liquidity event rather than a signal of company-level stress.

Corporate Governance Expert

TL;DR The Form 144 documents a compliance disclosure for an exercised option and planned sale; it meets Rule 144 reporting expectations.

The notice identifies the nature of acquisition as a stock option exercise from the issuer, financed with cash, and records the broker and planned trade date. The filer’s statement that there are no undisclosed material adverse facts and the absence of other recent sales aligns with standard Rule 144 compliance practice. For governance monitoring, this filing is informational and does not, by itself, indicate problematic insider conduct.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	36287	4591152.89	64180890	08/12/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/12/2025	Stock Option Exercise	Issuer			36287	08/12/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Ingredion's (INGR) Form 144 disclose?

The Form 144 discloses a proposed sale of 36,287 common shares valued at $4,591,152.89, to be sold on the NYSE approximately on 08/12/2025.

How were the shares acquired for the INGR Form 144 filing?

The shares were acquired on 08/12/2025 by stock option exercise from the issuer, with payment made in cash.

Which broker is handling the proposed sale in the Form 144?

The filing lists Fidelity Brokerage Services LLC at 900 Salem Street, Smithfield, RI, as the broker for the proposed sale.

Has the filer sold other Ingredion securities in the past three months?

No. The Form 144 states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

What representations does the filer make on the Form 144?

The filer represents by signing that they do not know any material adverse information about the issuer that has not been publicly disclosed and includes the standard Rule 10b5-1 note if applicable.